November 26, 2012

No compensation VEGF expression follow antisense inhibition BCL 2 activities

Antisense oligonucleotides (management) has been used for prostate cancer model for growth regulatory proteins, and at least one oligosaccharides (against BCL  has reached the clinical test. We've found that in LNCaP cell, mono - and double function management, the relative inhibitory expression, as compensation, the base class library 2 inhibition caspase 3 (apoptosis promoter) activities, and increase the expression of androgen receptor (AR) and p300 and il - co catalyst. In addition, the prostate specific membrane antigen (PSMA) and (may be its regulators) interferon (IFN) rise. 14 protein distributed between regulators of apoptosis, androgen control, differentiation antigen and autocrine mediated growth has been inspection. We put these findings including vascular endothelial growth factor (VEGF), promote angiogenesis, not through the compensation significant change, so do not need additional supervision for repression BCL 2 treatment is effective (such as caspase 3).

Posted by: biomichael825 at 03:42 PM | No Comments | Add Comment
Post contains 149 words, total size 1 kb.

Comments are disabled. Post is locked.
8kb generated in CPU 0.0053, elapsed 0.0423 seconds.
33 queries taking 0.0384 seconds, 45 records returned.
Powered by Minx 1.1.6c-pink.